Protalix Biotherapeutics Receives Research Grant of over $6 Million from the Israeli Government’s Office of the Chief Scientist  
3/11/2009 10:55:26 AM

CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (NYSE Alternext US:PLX), announced today that the Office of the Chief Scientist (“OCS”) of Israel's Ministry of Industry, Trade and Labor has awarded a grant of over $6 million to the Company for calendar year 2009. The OCS awarded the grant to the Company to promote the advancement of the Company’s clinical and preclinical drug development programs.